Clinical trials: HFpEF
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Heart Failure With Preserved Ejection Fraction
Efficacy of an m-Health Cardiac Rehabilitation Program in Heart Failure With Preserved Ejection Fraction
Heart failure (HF) portends substantial morbidity, mortality, and health care costs in the United States and the prevalence of heart failure with preserved ejection fraction (HFpEF) relative to HF with reduced ejection fraction…
- Trial name
- NCT05002075
- Testing
- m-health cardiac rehabilitation
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure, Diastolic, Heart Failure, Preserved Ejection Fraction
Relative Importance of Cardiovascular Risk Factors and Echocardiographic Parameters Affecting Left Atrial Strain
The goal of this observational study is to learn about left atrial reservoir strain in patients with heart failure with preserved ejection fraction.
- Trial name
- RICH-LAST (NCT05638230)
- Testing
- Left atrial reservoir strain
- Where
- South Korea
- Volunteers
- 2,500 people
- Sponsor
- Yonsei University
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
- Trial name
- SP9In-HFpEF (NCT05312021)
- Testing
- IMR-687
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure With Preserved Ejection Fraction
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.
- Trial name
- NCT05322616
- Testing
- JK07
- Where
- 7 sites in United States
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure With Preserved Ejection Fraction
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo.
- Trial name
- HFpEF (NCT05284617)
- Testing
- HU6
- Where
- 15 sites in United States
- Volunteers
- 67 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-STEP-HFpEF (NCT06914102)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 58,387 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
This study seeks to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and to demonstrate the advantages of EAT composition imaging (a) in advancing the understanding of the…
- Trial name
- NCT07178145
- Testing
- GLP-1RA
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- University of Virginia
Heart Failure, Diastolic
Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction
Part I: Week 0-12: Quantify the effects of lower heart rate (HR) elevation on symptoms and function in patients with heart failure with preserved ejection fraction (HFpEF).
- Trial name
- PACE HFpEF (NCT04546555)
- Testing
- Dual chamber pacemaker, Accelerated Physiologic Pacing, Nocturnal Pacing
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Daniel L Lustgarten
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure With Preserved Ejection Fraction
Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.
- Trial name
- CNEPi (NCT03506412)
- Testing
- Entresto™ 49Mg-51 mg tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and…
- Trial name
- EMBARK-HFpEF (NCT04766892)
- Testing
- mavacamten
- Where
- 21 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Chronic Heart Failure
Prediabetes and Newly Diagnosed Diabetes in Chronic Heart Failure
The aim the study is to determine the prevalence of prediabetic dysglycemia and newly diagnosed diabetes among individuals with CHF(chronic heart failure) in sohag university hospital patients .
- Trial name
- NCT05090202
- Testing
- hbA1C
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Heart Failure
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
- Trial name
- AURORA-HFpEF (NCT06122779)
- Testing
- BMS-986435
- Where
- 86 sites in United States, Argentina and 9 more
- Volunteers
- 227 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure
The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction
Gut microbiota play an important role in normal cardiovascular function and pathophysiology of cardiovascular diseases. Patients with heart failure (HF) have substantial hemodynamic changes which lead to intestinal hypoperfusion…
- Trial name
- NCT02728154
- Testing
- Blood Sample, Stool Sample
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Florida
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
- Conditions
- Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03624010
- Testing
- Levosimendan
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tenax Therapeutics, Inc.
Type 2 Diabetes, Diabetic Cardiomyopathies
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
- Conditions
- Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT04826159
- Testing
- IMB-1018972
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
HFpEF - Heart Failure With Preserved Ejection Fraction, Cardiac Catheterisation
Can Tiny Bubbles Offer an Alternative to Catheters for Assessing Pressures Inside the Heart? Investigating Ultrasound Contrast Agents as Pressure Sensors Against Gold Standard Catheter Pressures in Cardiac Catheterisation Patients.
The goal of this clinical trial is to investigate if ultrasound contrast agents can be used to estimate filling pressures inside the heart in patients with suspected heart disease.
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, Cardiac Catheterisation, Heart Disease
- Trial name
- SonoHeart (NCT07416279)
- Testing
- Contrast Echocardiography
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- King's College London